Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,724.68
    +1,327.23 (+2.63%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Cigna to Take Over Express Scripts (ESRX) for $67 Billion

Zacks Equity Research
Updated

Integrating medical care and pharmacy benefits under one roof, Express Scripts Holding Company ESRX recently announced that it is getting acquired by Cigna Corporation CI, a global health insurance company. The acquisition is expected to be completed by Dec 31, 2018. Post the acquisition, the combined company will invest $200 million in its charitable foundation to support the communities in which it operates.

Per the definitive agreement, Cigna will take over Express Scripts in a cash and stock transaction worth $67 billion. Notably, this includes Cigna's assumption of approximately $15 billion debt of Express Scripts. Express Scripts is the largest pharmacy benefits manager.

Express Scripts sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Express Scripts’ stock has outperformed the industry in the past year. Specifically, the company’s shares have gained 19.7% compared with the industry's rally of 13.8%.

Under the terms of the deal, Cigna will pay $48.75 in cash and 0.2434 shares of stock of the newly combined company. Upon closure, Express Scripts’ shareholders will own approximately 36% of the combined company.

ADVERTISEMENT

The transaction will result in total cost synergies of $650 million and double-digit accretion to earnings in the first year after closure. As a result, Cigna expects the deal to increase earnings per share from $18 to $20-$21 in 2021. The latest acquisition has been undertaken solely to enhance customer base and improve ‘Patient-Provider Alignment’.

Express Scripts Holding Company Price

 

Express Scripts Holding Company Price | Express Scripts Holding Company Quote


U.S. Healthcare Leads the M&A Game

Mergers and acquisitions (M&A) have been the key driver of the U.S. healthcare space, lately. Glancing through the major acquisitions of the recent past, Becton, Dickinson and Company’s BDX acquisition of C. R. Bard, and JOHNSON & JOHNSON’s buyout of Actelion deserve a mention.

In fact, health insurers are trying to consolidate with pharmacy benefits managers to streamline and cut costs in the drug supply chain. Notably, the latest buyout of Express Scripts comes just three months after a drug chain and a pharmacy giant CVS Health Corp CVS agreed to take over the nation's third-largest health insurer Aetna.

Coming to the post-acquisition impacts, we believe that the latest development will pose a big threat to UnitedHealth Group Incorporated (UNH), the largest U.S. health insurer, with its own pharmacy benefits unit, and CVS Health after it completes the merger with Aetna.

The move is also expected to nullify threats from Amazon.com Inc., which is making huge expansion in the world of pharmacy business. Recently, the e-commerce giant announced a joint venture with JPMorgan Chase & Co. and Warren Buffett's Berkshire Hathaway to curb medical costs for their employees.

What are the Moody’s Ratings for Express Scripts?

Moody's Investors Service, the rating services arm of Moody’s Corporation, placed the Baa2 senior unsecured long-term ratings to Express Scripts. Notably, obligations rated Baa are subject to moderate-credit risk. However, the latest rating has been kept under review with a tag of ‘direction uncertain’ by Moody’s.

Moody’s has not rated Express Scripts with high-credit risk because of its solid position as a leading pharmacy benefit manager, moderate leverage and strong cash flow.

However, Moody’s is worried about Express Scripts’ high customer concentration and pricing pressure. Further, the company’s ongoing dispute with Anthem, Inc — its largest customer — is a concern.

Per Moody’s, Express Scripts experienced declining script volume and higher-than-typical customer losses. Other challenges include fewer generic drug introductions, softening mail order growth trends, client focus on cost savings and transparency.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Cigna Corporation (CI) : Free Stock Analysis Report
 
Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
 
CVS Health Corporation (CVS) : Free Stock Analysis Report
 
Express Scripts Holding Company (ESRX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research